ADRU - BLDRS Europe Select ADR Index Fund
| Previous Close | 23.0800 |
| Open | 22.8538 |
| Bid | 22.8000 x 100 |
| Ask | 22.9100 x 400 |
| Day's Range | 22.7400 - 22.7400 |
| 52 Week Range | 20.5900 - 24.6500 |
| Volume | 90 |
| Avg. Volume | 1,298 |
| Net Assets | 16.65M |
| NAV | 22.20 |
| PE Ratio (TTM) | 267.53 |
| Yield | 3.30% |
| YTD Return | -2.21% |
| Beta (3y) | 0.90 |
| Expense Ratio (net) | 0.30% |
| Inception Date | 2002-11-13 |
- Market Realist•5 days ago
Novartis’s 1Q18 Estimates: Expectations for Sandoz
Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.
- Market Realist•14 days ago
Assessing the Performance of Novartis Stock in 1Q18
Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company that specializes in researching, developing, manufacturing, and marketing a broad range of healthcare products.
- Market Realist•last month
How AstraZeneca’s Other Products Portfolio Performed in 4Q17
What's Driving AstraZeneca’s Valuation in March 2018?
- Market Realist•2 months ago
Sanofi’s Generics and Consumer Healthcare Portfolios in 4Q17
Must-Read Notes on Sanofi's 4Q17 Earnings
Market Realist•2 months agoHow the Ablynx Acquisition Strengthens Sanofi’s R&D Strategy
Sanofi (SNY) is consistently investing in and focusing on its R&D (research and development) strategy. The company has a number of key technology platforms driving its multitargeting strategy in R&D. Sanofi spends ~15% of its total sales on R&D. In recent years, Sanofi has transformed its R&D approach and has shifted toward biologics and combination therapies.
- Market Realist•3 months ago
Novartis’s 4Q17 Earnings: Segment-Wise Revenues
Must-Read Notes on Novartis’s 4Q17 and 2017 Earnings
Market Realist•3 months agoShingrix Could Be a Long-Term Growth Driver for GlaxoSmithKline
On October 20, 2017, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) Zoster vaccine recombinant and adjuvanted vaccine, Shingrix, as a preventive measure against herpes zoster infection of shingles for adults over 50 years. This approval was based on solid efficacy, safety, and immunogenicity demonstrated by this non-live, recombinant subunit vaccine phase three program consisting of around 38,000 people.
- Market Realist•3 months ago
Inside Novartis’s 4Q17 Earnings: Analyst Estimates
Novartis’s 4Q17 Earnings: Behind the ExpectationsA look at Novartis’s earnings
Market Realist•3 months agoWhy Mizuho Securities Upgraded Teva Pharmaceutical to a ‘Buy’
Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate?Teva stock upgraded by Mizuho Securities
- Market Realist•7 months ago
How Is Novartis’s Lucentis Positioned after 1H17?
In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis.
- Market Realist•7 months ago
How TEVA’s Respiratory Franchise Is Positioned after 1H17
In 1H17, Teva Pharmaceutical's (TEVA) respiratory franchise reported revenues of ~$626 million, or ~8% lower YoY (year-over-year).
- Market Realist•8 months ago
AstraZeneca’s Segment-Wise Performance in 2Q17
At constant exchange rates, AstraZeneca reported an 8% decline in its product sales of ~$4.9 billion during 2Q17.
- Market Realist•8 months ago
GlaxoSmithKline’s Vaccines Business in 2Q17
GlaxoSmithKline's (GSK) vaccine business includes meningitis vaccines, influenza vaccines, and the established vaccines in its portfolio.
- Market Realist•8 months ago
Understanding Novartis’s Recent Developments after 2Q17
Novartis is focused on integrated drug development as well as centralized operations, and its new organizational structure has proven to be beneficial.
- Market Realist•8 months ago
Performance of Sanofi’s Established Products in 2Q17
Sanofi’s (SNY) established products contributed over 29.5% of its total revenue in 2Q17. Established product revenue, which fell 2.3% at constant exchange rates in 2Q17, stood at 2.6 billion euros. Lower…...
- Market Realist•9 months ago
GlaxoSmithKline’s 2Q17 Earnings: HIV Business
GSK's HIV Products franchise reported growth of 29.0% to ~1.1 billion pounds in 2Q17 compared to 2Q16.
- Market Realist•9 months ago
Novartis’s 2Q17 Estimates: Alcon, the Eye Care Business
Analysts expect Novartis's 2Q17 revenues for Alcon to increase operationally following strong sales of products from the vision care franchise.
